Abstracts
12 June 2009
Vol. 3 No. 3 (2009)
https://doi.org/10.4081/hmr.v3i3.571

High dose chemotherapy and autologous transplantation in anti-CD20 antibodies era: still a place?

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
190
Views
262
Downloads

Authors

U Vitolo
support@pagepress.org
A Chiappella
B Botto
High dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) is recommended in young (<65 years) patients with diffuse large B-cell lymphoma (DLBCL) without a complete response (CR) after first line chemotherapy or in patients with chemosensitive DLBCL at relapse. According to Italian Society of Haematology guidelines and others, this approach, as first line treatment should be considered in young patients with an intermediate/high or high-risk according to the age-adjusted International Prognostic Index (aa-IPI) only in approved study protocols.1,2 So far, in the pre-rituximab era, no clear benefits were shown in such patients, and conflicting results were generated in randomized studies, with similar survival rates in patients receiving either first-line HDC and ASCT, or standard chemotherapy without rituximab.3-7

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



High dose chemotherapy and autologous transplantation in anti-CD20 antibodies era: still a place?. (2009). Hematology Meeting Reports, 3(3). https://doi.org/10.4081/hmr.v3i3.571